Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i21.106939

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 21

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2005)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-6) series.

Item

Count

PDF

HTML

1261

Figures (1-7)

171

Tables (1-6)

194

Sum=1678

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

218

Sum=237

Jun 7, 2025 (publication date) through Aug 16, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939

Table 4 Treatment-emergent adverse events in the 103 patients of the matched dataset, n (%)

Toxicities	Experimental group (n = 26)			Control group (n = 77)			P value for grade 1-2	P value for grade 3-4
Toxicities	Grade 0	Grade 1-2	Grade 3-4	Grade 0	Grade 1-2	Grade 3-4	P value for grade 1-2	P value for grade 3-4
Anemia	8 (30.8)	15 (57.7)	3 (11.5)	47 (61.0)	29 (37.7)	1 (1.3)	0.1197^a	0.2451^b
Neutropenia	18 (69.2)	7 (26.9)	1 (3.8)	58 (75.3)	14 (18.2)	5 (6.5)	0.4996^a	1^b
Leukocytopenia	14 (53.8)	11 (42.3)	1 (3.8)	55 (71.4)	18 (23.4)	4 (5.2)	0.1088^a	0.3667^b
Thrombocytopenia	17 (65.4)	9 (34.6)	0 (0.0)	62 (80.5)	15 (19.5)	0 (0.0)	0.1902^a	1^b
Proteinuria	21 (80.8)	5 (19.2)	0 (0.0)	70 (90.9)	7 (9.1)	0 (0.0)	0.2984^a	1^b
Aspartate transaminase increased	18 (69.2)	7 (26.9)	1 (3.8)	56 (72.7)	20 (26.0)	1 (1.3)	1^a	1^b
Alanine transaminase increased	20 (76.9)	5 (19.2)	1 (3.8)	65 (84.4)	12 (15.6)	0 (0.0)	0.8985^a	1^b
Alkaline phosphatase increased	21 (80.8)	5 (19.2)	0 (0.0)	69 (89.6)	7 (9.1)	1 (1.3)	0.1732^b	1^b
Blood bilirubin increased	20 (76.9)	5 (19.2)	1 (3.8)	61 (79.2)	16 (20.8)	0 (0.0)	1^a	1^b
Triglycerides increased	20 (76.9)	4 (15.4)	2 (7.7)	67 (87.0)	10 (13.0)	0 (0.0)	0.7475^b	0.4967 ^b
Nausea	18 (69.2)	8 (30.8)	0 (0.0)	47 (61.0)	30 (39.0)	0 (0.0)	0.6076^a	1^b
Vomiting	19 (73.1)	7 (26.9)	0 (0.0)	61 (79.2)	16 (20.8)	0 (0.0)	0.7054^a	1^b
Fatigue	18 (69.2)	8 (30.8)	0 (0.0)	68 (88.3)	9 (11.7)	0 (0.0)	0.0332^b	1^b
Fever	24 (92.3)	2 (7.7)	0 (0.0)	73 (94.8)	4 (5.2)	0 (0.0)	0.6407^b	1^b
Diarrhea	24 (92.3)	1 (3.8)	1 (3.8)	71 (92.2)	6 (7.8)	0 (0.0)	0.6759^b	1^b
Peripheral neurotoxicity	25 (96.2)	1 (3.8)	0 (0.0)	77 (100.0)	0 (0.0)	0 (0.0)	0.2524^b	1^b
Hand-foot syndrome	23 (88.5)	3 (11.5)	0 (0.0)	73 (94.8)	4 (5.2)	0 (0.0)	0.3648^b	1^b
Hypertension	24 (92.3)	1 (3.8)	1 (3.8)	72 (93.5)	4 (5.2)	1 (1.3)	1^b	1^b

^aP values were calculated by χ² test.

^bP values were calculated by Fisher’s exact test.

The control group received chemotherapy combined with bevacizumab; the experimental group received chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy.

Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Chemotherapy plus bevacizumab with or without anti-programmed death 1 immunotherapy as the second-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(21): 106939
URL: https://www.wjgnet.com/1007-9327/full/v31/i21/106939.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i21.106939